What happened
EU-Startups reported on August 28 that Clementine, a Maastricht-based hearing-care startup, raised €1.7 million in seed funding. The round was led by Amsterdam-based HealthTech investor Healthy.Capital, according to the outlet. Clementine says its platform uses an AI agent called Matthew to answer questions from prospective hearing-care patients, address barriers to seeking treatment and support clinics with lead follow-up.
EU-Startups reported that Clementine, also known as ClementineAI, raised €1.7 million in seed funding. The outlet said the round was led by Healthy.Capital, an Amsterdam-based early-stage HealthTech investor. The company was founded in 2024 and is headquartered in Maastricht, in the Dutch province of Limburg. EU-Startups identified Vince van de Weijer as Clementine’s founder and chief executive. The financing amount, lead investor and company details are attributed here to EU-Startups and were not independently confirmed from a public filing or primary financing document in the supplied material.
The reported product is a platform built for hearing-care providers. At its center is Matthew, which Clementine describes as an AI hearing-care agent that communicates directly with prospective patients. According to EU-Startups, the agent is intended to answer questions at any time, provide information about hearing care, address emotional and practical obstacles, and guide users toward care. The report also says the system can help clinics handle inquiries and turn calls into bookings. It does not identify the underlying AI model, explain how responses are reviewed, or provide test results for accuracy, escalation or safety.
EU-Startups said the financing followed a recent expansion of Clementine’s commercial footprint through a partnership with Zoolstra, a marketing agency serving hearing clinics and hearing groups in the United States and Canada. The outlet reported that Clementine plans to use the funding to develop its AI capabilities and broaden partnerships with hearing clinics, optical retailers and other healthcare organizations. The source does not specify the partnership’s contractual scope, the number of active customers, the markets in which the platform is available or whether the reported funding has already been fully deployed.
Source details: eu-startups.com ↗
Why it matters
The reported investment is aimed at applying conversational AI to a specific healthcare access problem: unanswered inquiries and delays before people seek hearing treatment. The source presents the platform as a way to extend clinic communications beyond staff availability, but it does not independently establish clinical benefits, patient outcomes, accuracy or regulatory status.
The significance of the reported investment lies in the use of AI at an early stage of the hearing-care journey rather than in diagnosis or treatment. Hearing clinics often depend on timely responses to inquiries, and a system that can handle basic questions outside normal staff hours could change how prospective patients enter the care process. EU-Startups frames Clementine’s product as a response to missed or delayed conversations, but the article does not independently demonstrate that the system increases access or improves hearing outcomes.
The potential public benefit is practical if the agent helps people understand available services and reach qualified professionals sooner. EU-Startups cited Clementine’s estimate that hearing loss affects 1.5 billion people worldwide, that nearly 80% of those affected never seek treatment and that people who do seek care typically wait more than eight years. Those figures are presented in the source as part of Clementine’s rationale; the supplied article does not identify their methodology or independently verify them. They should therefore be treated as company-linked context, not established findings from this report.
The healthcare setting also makes the claims harder to evaluate than ordinary customer-service automation. An AI system speaking with people about a possible disability may influence whether they seek care, what they expect from a clinic and how they interpret symptoms. Its usefulness will depend on the boundaries between general information, triage and medical advice, as well as on how it handles uncertainty and routes people to human professionals. The source provides no evidence about those safeguards, so the funding is best understood as an industry development rather than proof of a validated healthcare intervention.
What to watch next
The important next evidence will be whether Clementine can show that Matthew improves completed appointments or access to appropriate care without introducing unsafe or misleading health guidance. The source does not disclose the round’s terms, the number of clinics using the system, the AI model behind it, performance data, privacy safeguards or the scope of its North American partnership.
The first question is whether Clementine publishes measurable results from real clinic use. Useful evidence would include response accuracy, rates of escalation to human staff, completed appointment rates, dropout rates and outcomes across different patient groups. The source gives none of these measures, and its descriptions of smoother communication and better outcomes remain company claims reported by EU-Startups.
Privacy and governance will be central as the platform expands. The article does not say what information Matthew collects, where conversations are stored, how long data is retained, whether patient consent is required or how clinics can audit and correct the system’s outputs. It also does not clarify whether the platform is intended only for lead engagement or whether it makes recommendations about urgency or care pathways. Those distinctions will affect the relevant safety and compliance obligations.
The commercial rollout will provide another test. EU-Startups reported a partnership covering hearing clinics and hearing groups in the United States and Canada, plus plans to work with optical retailers and other healthcare organizations. It remains unknown how many organizations have adopted the platform, whether the partnership has produced bookings, whether the system is available beyond pilot settings and how Clementine will support human oversight across jurisdictions. Further reporting should also establish the round’s terms, total funding and whether independent investors or customers confirm the company’s account.
